Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease
Identifieur interne : 002624 ( Main/Exploration ); précédent : 002623; suivant : 002625Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease
Auteurs : Jenner [Royaume-Uni] ; D. T. Dexter [Royaume-Uni] ; J. Sian [Royaume-Uni] ; A. H. V. Schapira [Royaume-Uni] ; C. D. Marsden [Royaume-Uni]Source :
- Annals of Neurology [ 0364-5134 ] ; 1992.
Abstract
We examine the evidence for free radical involvement and oxidative stress in the pathological process underlying Parkinson's disease, from postmortem brain tissue. The concept of free radical involvement is supported by enhanced basal lipid peroxidation in substantia nigra in patients with Parkinson's disease, demonstrated by increased levels of malondialdehyde and lipid hydroperoxides. The activity of many of the protective mechanisms against oxidative stress does not seem to be significantly altered in the nigra in Parkinson's disease. Thus, activities of catalase and glutathione peroxidase are more or less unchanged, as are concentrations of vitamin C and vitamin E. The activity of mitochondrial superoxide dismutase and the levels of the antioxidant ion zinc are, however, increased, which may reflect oxidative stress in substantia nigra. Levels of reduced glutathione are decreased in nigra in Parkinson's disease; this decrease does not occur in other brain areas or in other neurodegenerative illnesses affecting this brain region (i.e., multiple system atrophy, progressive supranuclear palsy). Altered glutathione metabolism may prevent inactivation of hydrogen peroxide and enhance formation of toxic hydroxyl radicals. In brain material from patients with incidental Lewy body disease (presymptomatic Parkinson's disease), there is no evidence for alterations in iron metabolism and no significant change in mitochondrial complex I function. The levels of reduced glutathione in substantia nigra, however, are reduced to the same extent as in advanced Parkinson's disease. These data suggest that changes in glutathione function are an early component of the pathological process of Parkinson's disease. The data presented suggest (1) there is oxidative stress in the substantia nigra at the time of death in advanced Parkinson's disease that manifests in terms of increased lipid peroxidation, superoxide dismutase activity, and zinc levels; (2) there is a major impairment of the glutathione pathway in Parkinson's disease; and (3) alterations in reduced glutathione levels may occur very early in the illness.
Url:
DOI: 10.1002/ana.410320714
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease</title><author><name sortKey="Jenner" sort="Jenner" uniqKey="Jenner" last="Jenner">Jenner</name></author><author><name sortKey="Dexter, D T" sort="Dexter, D T" uniqKey="Dexter D" first="D. T." last="Dexter">D. T. Dexter</name></author><author><name sortKey="Sian, J" sort="Sian, J" uniqKey="Sian J" first="J." last="Sian">J. Sian</name></author><author><name sortKey="Schapira, A H V" sort="Schapira, A H V" uniqKey="Schapira A" first="A. H. V." last="Schapira">A. H. V. Schapira</name></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:74811F58E1FCA85454B7D4547082ACBC506D9029</idno><date when="1992" year="1992">1992</date><idno type="doi">10.1002/ana.410320714</idno><idno type="url">https://api.istex.fr/document/74811F58E1FCA85454B7D4547082ACBC506D9029/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002621</idno><idno type="wicri:Area/Main/Curation">002281</idno><idno type="wicri:Area/Main/Exploration">002624</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease</title><author><name sortKey="Jenner" sort="Jenner" uniqKey="Jenner" last="Jenner">Jenner</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Parkinson's Disease Society Experimental Research Laboratories, Pharmacology Group, Biomedical Sciences Division, King's College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Dexter, D T" sort="Dexter, D T" uniqKey="Dexter D" first="D. T." last="Dexter">D. T. Dexter</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Parkinson's Disease Society Experimental Research Laboratories, Pharmacology Group, Biomedical Sciences Division, King's College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Sian, J" sort="Sian, J" uniqKey="Sian J" first="J." last="Sian">J. Sian</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Parkinson's Disease Society Experimental Research Laboratories, Pharmacology Group, Biomedical Sciences Division, King's College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Schapira, A H V" sort="Schapira, A H V" uniqKey="Schapira A" first="A. H. V." last="Schapira">A. H. V. Schapira</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Neurological Science, Royal Free Hospital School of Medicine, National Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Parkinson's Disease Society Brain Bank, University Department of Clinical Neurology, Institute of Neurology, National Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1992">1992</date><biblScope unit="volume">32</biblScope><biblScope unit="issue">S1</biblScope><biblScope unit="supplement">S1</biblScope><biblScope unit="page" from="S82">S82</biblScope><biblScope unit="page" to="S87">S87</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">74811F58E1FCA85454B7D4547082ACBC506D9029</idno><idno type="DOI">10.1002/ana.410320714</idno><idno type="ArticleID">ANA410320714</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We examine the evidence for free radical involvement and oxidative stress in the pathological process underlying Parkinson's disease, from postmortem brain tissue. The concept of free radical involvement is supported by enhanced basal lipid peroxidation in substantia nigra in patients with Parkinson's disease, demonstrated by increased levels of malondialdehyde and lipid hydroperoxides. The activity of many of the protective mechanisms against oxidative stress does not seem to be significantly altered in the nigra in Parkinson's disease. Thus, activities of catalase and glutathione peroxidase are more or less unchanged, as are concentrations of vitamin C and vitamin E. The activity of mitochondrial superoxide dismutase and the levels of the antioxidant ion zinc are, however, increased, which may reflect oxidative stress in substantia nigra. Levels of reduced glutathione are decreased in nigra in Parkinson's disease; this decrease does not occur in other brain areas or in other neurodegenerative illnesses affecting this brain region (i.e., multiple system atrophy, progressive supranuclear palsy). Altered glutathione metabolism may prevent inactivation of hydrogen peroxide and enhance formation of toxic hydroxyl radicals. In brain material from patients with incidental Lewy body disease (presymptomatic Parkinson's disease), there is no evidence for alterations in iron metabolism and no significant change in mitochondrial complex I function. The levels of reduced glutathione in substantia nigra, however, are reduced to the same extent as in advanced Parkinson's disease. These data suggest that changes in glutathione function are an early component of the pathological process of Parkinson's disease. The data presented suggest (1) there is oxidative stress in the substantia nigra at the time of death in advanced Parkinson's disease that manifests in terms of increased lipid peroxidation, superoxide dismutase activity, and zinc levels; (2) there is a major impairment of the glutathione pathway in Parkinson's disease; and (3) alterations in reduced glutathione levels may occur very early in the illness.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Jenner" sort="Jenner" uniqKey="Jenner" last="Jenner">Jenner</name></region><name sortKey="Dexter, D T" sort="Dexter, D T" uniqKey="Dexter D" first="D. T." last="Dexter">D. T. Dexter</name><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name><name sortKey="Schapira, A H V" sort="Schapira, A H V" uniqKey="Schapira A" first="A. H. V." last="Schapira">A. H. V. Schapira</name><name sortKey="Sian, J" sort="Sian, J" uniqKey="Sian J" first="J." last="Sian">J. Sian</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002624 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002624 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:74811F58E1FCA85454B7D4547082ACBC506D9029
|texte= Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease
}}
| This area was generated with Dilib version V0.6.23. |  |